FDA approves Airduo ® Digihaler ™ for asthma sufferers

Airduo® Digihaler ™ approval is based on a review of the supplementary new drug application (sNDA) submitted by Tyva to the FDAAirduo® Digihaler ™ combines a breath-driven multi-dose dry powder inhaler with fluoroteocason of propylene acid," in which fluorococinacinis is an inhaling corticosteroid (ICS) that helps reduce inflammation in the lungs, and Sametero is a long-acting beta-2 epinephrine-boosting (LABA) that helps the muscles around the airways of the lungs relax to prevent symptomsAirduo ® Digihaler ™ approved for low, medium and high doses: 55/14 mcg, 113/14 mcg, 232/14 mcg, twice a dayAs a fixed-dose combination asthma therapy with ICS and LABA, Airduo ® Digihaler ™ contain the same active ingredient as a dvair diskus ®, which is approved for low, medium and high doses: 100/50 mcg, 250/50 mcg, 500/50 mcgDrNabeel Farooqui, an assistant professor of medicine at Indiana University School of Medicine, said: "Even the most diligent asthma sufferers, despite their best efforts, may not realize that they are not following their treatment planThe ability to measure their suction rate and track their maintenance drug use and how often they use inhalers may provide important data and insights to help with treatment discussions with doctorsAs a doctor, it is exciting that my patients can share this kind of information with meoriginal origin: Teva Announces FDA of Approvalofthe® Digihaler ™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powderoriginal title: First Digital Maintenance Inhaler Therapy! FDA approves Tiwa Air Duo Digihaler (fluorotecaztifano/sametero)